Your Cell-Therapy Specialized CDMO Cell-Easy is a CDMO specialized in Cell Therapy. We support biotech, pharma, and public institutions with GMP development and manufacturing. Our mission: accelerate your Cell Therapy’s path to market, with patient access as our priority. ATMPs are not conventional biologics — they are living drugs. Our team brings hands-on expertise in cell culture across all cell types, engineered or not, addressing challenges in development, GMP manufacturing, and QC. Beyond core CDMO services — process diagnostics, development, GMP production, cell banking, cryostorage, and delivery — we also support sourcing of human biological materials and clinical trial setup, …

200 similar entities Type: Startup Activities: biotech healthtech manufacturing Technologies: Synthetic Biology

Our mission is to empower our customers to improve human health. Crown Bioscience is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to deliver integrated preclinical and translational research solutions, supporting programs from target discovery through clinical development. Our portfolio includes more than 2,800 patient-derived xenograft (PDX) models and approximately 1,000 tumor organoid models across 35 cancer indications, supported by expertise in in vivo, in vitro, ex vivo, and in silico research. Combined with advanced laboratory services, multiomics capabilities, and data science, we help …

437 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Human-on-a-Chip Company Hesperos, Inc. is accelerating drug discovery by providing safety and efficacy testing of chemicals and novel therapeutics for the pharmaceutical, cosmetic, and food industries using its patented, Human-on-a-Chip platform. Bringing together biologists, surface chemists, and engineers, our team is producing some of the world's most advanced organs-on-a-chip platforms. From gene expression to electrophysiology, we recreate key components of organs in an interconnected, functional system. Chemically patterned microchips enable real-time, non-invasive monitoring of organ function where we use sophisticated measurement techniques to detect minute changes. This breakthrough technology enables unprecedented visibility into specific disease states and how the …

83 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We turn tumor response into treatment decisions. Okomera has developed a proprietary technology platform that transforms patient biopsies into multiple miniaturized tumor avatars, enabling rapid assessment of treatment response in real-world conditions. Designed as a decentralized lab for clinicians and biopharma companies, the platform seamlessly converges cutting-edge hardware, software, and biological technologies into a single integrated system, making functional precision medicine accessible at scale. We are building a future where every cancer patient receives the right treatment from the start.

512 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. Research, Innovation, Technology, In-vitro, 3D Cell Culture, Organ-on-Chip, Respiratory diseases, Drug Development, Drug Discovery, Preclinical Services, Safety, Efficacy, …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Acoustic Cell Processing Solution 🚀 Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. By precisely controlling levitated cells with sound waves, our systems handle cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. This technology enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing for the handling of tens of milliliters per minute. Such capabilities are critical for scaling applications from research to clinical and industrial use. 💡Today, we have achieved proof-of-concepts …

90 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

making a difference Greiner Bio-One: Innovative solutions for your hospitals, laboratories and research facilities We specialize in the development, production and distribution of high-quality plastic products for laboratories worldwide. As a reliable technology partner, we support hospitals, research institutions, laboratories as well as the diagnostic, pharmaceutical and biotechnology industries with customized solutions. Our focus: ☑ Preanalytics: We are setting new standards in safety and efficiency with innovative collection systems for blood, urine and saliva sampling. Our customized digital solutions (Greiner eHealth Technologies) optimize processes and increase patient safety in laboratories and medical practices. ☑ BioScience: We offer highly specialized products …

481 similar entities Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Engineered protein polymers for cost‐effective, reliable cell growth MarraBio designs, engineers and constructs bacterial protein polymers that embed biological signals to support industrial cell growth. Our multifunctional, cost-effective materials simplify supply of biological cues, e.g. cell adhesion and growth factors for both 2D and 3D workflows.

351 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Smart control of the cell microenvironment - Bioengineered in vitro assays Experts in cell microenvironment control. At the forefront of the new challenges in biology, 4Dcell offers more reliable innovative study models, which are closer to the natural environment of the cell. 4Dcell technologies provide solutions for a myriad of applications. Among them, we highlight models for cancer, immune system, organs such as heart or gut, circulating cells, wound healing, neuronal network, stem cells and genetic disorders such as laminopathy. Years of research have led 4Dcell to develop an innovative 3D cell culture technology that enables the acquisition of more …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research

138 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Beyond LNPs. Beyond the liver. A unique plant-based platform to unlock the potential of RNA therapies beyond vaccination Our mission is to unlock the full therapeutic potential of RNA medicines beyond the limitations of conventional lipid nanoparticles (LNPs) delivery and IVT RNA production systems, especially for in vivo cell-therapy developers. Serendip Innovations is developing a next-generation RNA platform that integrates both RNA manufacturing and targeted delivery beyond the liver. Using a unique plant-based production system and programmable phytovirus-like particles (phytoVLP), we generate functional RNAs directly encapsulated into a proprietary non-viral vector designed for targeted extrahepatic delivery, repeat dosing, and scalable …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

311 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the Hidden Chemistry of Microbiomes for Next-Generation Therapeutics with ISMM • Expanding Customer Pipelines Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover …

109 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics Synthetic Biology Generative A.I. A.I. - Machine Learning

Precision Transfections Trince is a spin-off company from Ghent University dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company's LumiPore transfection platform, which is covered by a portfolio of pending patents, combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane. It can be used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology not only …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are reimagining the entire drug discovery process from first principles with an AI-first approach. Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people. Every day, and with each new breakthrough, we’re getting closer to achieving our ambitious mission to one day solve all disease Drug Discovery and Design, machine learning, research, engineering, chemistry, and biology

208 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I.

The glyco design company Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved. Bioproduction and Cell …

84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

385 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

"Designs the immunotherapy of tomorrow" At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders. We're developing a breakthrough cell therapy platform with the potential to: • Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, …

178 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Transform how you model human biology. Ricoh Biosciences is a global leader in biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human biology and accelerating …

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing innovative therapies to patients Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select …

135 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles. We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency …

93 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Easily detect your biological nanoparticles A spin-off from the Institut d'Optique Graduate School, Université Paris-Saclay, UNVEIL is a deeptech start-up that facilitates the development and production of biologics (drugs derived from living organisms, such as messenger RNA vaccines, as opposed to chemical ones). These biologics (gene therapy, RNA vaccines, etc.) are transported to the target site in the human body by nanometric vectors (viruses or lipid nanoparticles). R&D and production of these biomedicines is hampered by the lack of effective technology to measure vector loading. UNVEIL has developped an optical, label-free instrument capable of quickly and easily measuring nanovector loading …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Alternative to Animal Testing for Drug Development Cherry Biotech is a biomedical technology (Organ on Chip) company that develops instruments for drug discovery and personalised medicine. Its mission is to replace animal testing by reconstructing human tissue (Organoids) in vitro for drug testing. Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates. By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert …

141 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

240 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotechnology company who supports scientists worldwide with high-end human cell culture products and services. At PromoCell, we help scientists do better research with a world-class portfolio of human primary, stem and blood cells as well as optimized cell culture media. With over 35 years of expertise, we are recognized globally for supplying scientists with the tools and support they need to do groundbreaking research. All our products comply with European biomedical conventions, ensuring human rights and donor privacy are always protected. Our ISO certifications demonstrate our absolute commitment to quality and our EXCiPACTTM GMP certification enables us to produce …

141 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OZ Biosciences creates, develops and commercializes life sciences reagents specialized in transfection and transduction OZ Biosciences is a product development company that creates, develops and commercializes delivery systems of bioactive materials (DNA, siRNA, proteins, antibodies...), intended for the worldwide scientific community and pharmaceutical industries. Our mission is to assist scientists to accelerate the rhythm of discoveries by offering them technologically advanced tools such as transfection reagents and other life science research products. Principal innovations are based on proprietary technologies such as Magnetofection (magnetic-assisted transfection or infection), Magneto-Biolistic, transfection reagents, transduction tools, mRNA and lipids-based delivery systems (LNP). Specialized and expert …

90 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We make the development of modern therapies faster, safer, and more affordable. Join us to create the future of health! We at CYTENA strive to empower our customers to serve patients faster and better. To accelerate workflows and bring new insights into biotherapeutic drug development, we provide precise control of individual cells through automation and microtechnology. Our instruments offer automated isolation of single cells with assurance of clonality and selection based on cell morphology. We can isolate many common cell types including bacteria. Our high viability rates make our instruments compatible with cell line development, single cell analysis, and other …

123 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Discovery Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications. Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over …

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems. CN Bio is a leading Organ-on-a-chip (OOC) company that enables scientists to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® Core microphysiological system, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Gut/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment, and function of their human counterparts in …

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

See life in color. Microscope module and AI solutions for chemistry-free longitudinal imaging of 2D/3D live biosamples The aim of our company is to develop and commercialize a non invasive microscopy module for functional monitoring of 3D cultures of human cells and complex tissues. Based on almost 10 years of research in the lab, our technology measures a signal characteristic of cell metabolism, by measuring fluctuations in the amount of light scattered by cell organelles. Our optical design is integrated into a module that can be attached to any commercial microscope and is compatible with the state of the art. …

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

AI for digital twin of cells DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, …

294 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning SaaS

Smart tools for cell biology Nanobiose’s mission is to provide pharma, biotech and cosmetic companies with better tools to improve their in vitro analysis of efficacy / safety of drug candidates. Nanobiose develops SecretCells®, an innovative lab-on-a-chip system to evaluate secreted biomarkers from 2D or 3D perfused cells. SecretCells® combines a microfluidic biochip (where the perfused 3D cell cultures stand) and a removable biosensor for a multiplexed on-line biomarkers analysis. While better mimicking in vivo like conditions, SecretCells® allows more accurate and more predictive results for the evaluation of drug candidates at early stages. SecretCells® is a very flexible solution …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Sensors Synthetic Biology

The CanVas platform is focused on developing novel cell therapies. The CanVas platform is spearheading the development of investigational allogeneic candidates for neurologic, rare and other serious diseases. Our world class team are dedicated to advancing a wave of investigational allogeneic products through excellence in translational research, clinical development and cell manufacturing. We are developing a pipeline of off-the-shelf cell therapies based on the pioneering Can-Vas platform. This could allow for the delivery of cell therapies to patients faster when they need it most and at greater scale. Our mission is to have a transformative impact on patients’ lives by …

245 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Smart VHH nanobody solutions – from standard to strategic. Cortalix – Smart VHH Nanobody Solutions Cortalix is a biotechnology company specializing in the discovery, engineering, and development of VHH nanobodies from both synthetic and immune libraries. We provide a full-service platform — from high-throughput screening and selection to production, functional testing, and advanced engineering such as CDR grafting and humanization. Our focus areas include molecular imaging, targeted radiotherapeutics, CAR-T immunotherapy, and next-generation diagnostics. What sets us apart is our ability to combine technical precision with creative scientific problem-solving, working as a true R&D partner rather than just a service provider. …

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the …

119 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We create all-in-one instruments that make high-throughput single-cell workflows easy thanks to droplet microfluidics At LiveDrop, we develop, build, and sell cutting-edge instruments and methods for high-throughput screening of biological cells and organisms—down to the single-cell level—using microfluidic droplets. Our solutions enable faster, more precise screenings through highly efficient, fully integrated bioassays. LiveDrop’s flagship platform, ModaFlow 4L5C, revolutionises cell screening, drug discovery, and secretome analysis with unparalleled speed and precision. It supports a wide range of applications, including monoclonal antibody discovery, single-cell secretome-based bioassays, high-throughput spheroid manufacturing for drug testing, directed evolution of microbes, and enzyme discovery. We value collaboration …

343 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We give access to the pulse of life Unlocking the Future of Cell Screening with Groundbreaking Innovation MicroOmix is a pioneering startup powered by patented technology from the CNRS and the University of Strasbourg, setting a new standard in high-throughput cell screening. Our cutting-edge platform analyzes cells based on the molecules they secrete, with a level of precision and resolution that is unrivaled. Secreted molecules are at the heart of critical biological processes—driving immune responses, cell migration, tissue regeneration, and differentiation. Emerging research reveals their pivotal role in disease progression and therapeutic effectiveness, but until now, accessing these insights has …

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ultimate predictability Since 1999, genOway aims at bridging the gap between preclinical findings and clinical success with advanced, genetically engineered preclinical models and solutions. From customized mice and rats to ready-to-use cell lines, our solutions provide increased predictability and accelerate therapeutic breakthroughs. We work with 17 of the world’s Top pharma companies—as well as leading biotech firms, CROs, and academic institutions. At the heart of genOway is a team of 150+ skilled professionals, from 17 nationalities, all committed to advancing preclinical research. What We Offer • A catalogue of validated, ready-to-use mice and cell lines—developed in partnership with biopharma leaders …

148 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A Path to SuperCellsTM Therapies GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCellsTM by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

159 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Turning adherent cells into barcoded reagents to accelerate drug discovery Semarion is transforming adherent cell assays for next-generation drug discovery. Our SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models in the same well, miniaturise assays, and generate richer biological data from existing microplate workflows. SemaCytes are ultra-miniaturised, optically barcoded microcarriers that function like microscopic Petri dishes. They carry small groups of adherent cells while preserving 2D morphology, can be handled with standard liquid handlers, cryopreserved for on-demand use, pooled for multiplexed assays, and decoded by high-content imaging. By decoupling cell preparation from …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

NUCLEIC ACID CAPTURE FOR LIQUID BIOPSY BIOCAPTIVA is an award-winning biotechnology company based in Edinburgh, dedicated to revolutionising liquid biopsy and nucleic acid (NA) extraction. Harnessing our proprietary msXTM polymer technology, we are addressing critical challenges in the liquid biopsy market, empowering breakthroughs in genetic disease detection, diagnosis, monitoring, and treatment. Our advanced extraction method ensures unparalleled cell-free NA yield and quality, driving progress in precision medicine and multi-omics research. What Sets Us Apart: Our Patented NA-Binding Polymers Our innovative, biocompatible NA-binding polymers offer unmatched benefits: Flexibility: Customisable coatings for diverse substrate formats, including bead-based systems and automated workflows. Versatility: …

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable …

330 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Single-use, Singularly Focused Charter Medical, part of the Solesis family of companies, is more than a single-use solutions supplier - we're a design partner. While we develop portfolio solutions that can be used off the shelf, Charter specializes in customizing single-use solutions to meet biopharma companies' unique processing needs, whether simple or complex. At Charter Medical, we’re on a mission to evolve single-use cell processing step-by-step with the needs of the biopharmaceutical innovators who count on us. With proven customization capabilities and an innovation roadmap that includes pioneering design and biomaterials. With industry-leading expertise and continuous improvement to simplify and …

80 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Delivering therapeutics directly into the cytosol of tumor cells to unlock previously undruggable cancer targets iDEL Therapeutics is a biotechnology company developing a pioneering drug delivery platform designed to transport therapeutic payloads directly into the cytosol of tumor cells. Our proprietary synthetic shuttle technology leverages a unique pan-cancer uptake mechanism that enables high intracellular drug exposure and sustained tumor retention while evading endosomal trapping. The platform is compatible with both small and large molecules, including nanobody-based therapeutics targeting oncogenes and tumor-directed cytotoxic payloads. iDEL Therapeutics is advancing a pipeline of innovative cancer therapies designed to unlock historically undruggable intracellular targets. …

114 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Semi-Permeable Capsules (SPCs) for single-cell analysis and multiomics at scale Atrandi Biosciences, founded in 2016, is a pioneering life sciences tool company transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology. This next-generation technology isolates tens of thousands of single cells within discrete, permeable compartments, allowing bulk reactions to proceed as usual while preserving single-cell resolution. SPCs have already unlocked previously inaccessible applications, such as high-throughput microbial and eukaryotic genomics, and are poised to enable true single-cell multiomics. Headquartered in Vilnius, Lithuania, Atrandi’s name, meaning “you discover” in Lithuanian, embodies the company’s mission to empower scientists to uncover the …

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reduce media costs and maximize cell viability. 3DBT: Crowding technology for meat-tech and biopharma. 3D Bio-tissues (3DBT) is a biotechnology company redefining the efficiency of cell-based therapies and cellular agriculture. We specialize in the development of macromolecular crowders—simple, powerful media additives designed to mimic the natural physiological environment, accelerating growth and significantly reducing operational costs. At the core of our innovation is a commitment to making complex biology scalable. By optimizing the way cells interact with their environment, we help our partners move from lab-scale success to industrial-scale reality. Our Core Solutions: CityMixTM | Transforming Cultivated Meat: The biggest barrier …

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster. Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process …

424 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

the control panel for the cell Nature is building tomorrow’s medicines. At Tolemy Bio, we are building the AI-native control panel for these cell-derived medicines, combining virtual cell models, big biological data, and wet-lab experimentation to help direct cellular systems toward better therapeutic outcomes. Our mission is to make cell biology more predictable, programmable, and scalable. Reach out to info@tolemy.bio learn more

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Preserving the PromiseTM - We believe the promise of cell and gene therapies starts with the integrity of a single cell. Preserving the PromiseTM The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future …

80 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Working at the frontier of microfluidics, automation and machine learning to accelerate cell-based medicines. Scaled Biolabs accelerates the discovery and development of complex cell-based medicines, such as stem cell therapies and cancer immunotherapies. Their full stack optimization engine reduces complexity and time to market, by leveraging high-throughput, micro-scale cell culture, automation, and deep data insight. It also powers internal, grant funded programs such as developing a new gold standard for manufacturing dopaminergic neurons to treat Parkinson’s disease. Microfluidics, Biomedical R&D, Bioreactor, Single-cell Biology, Bioengineering, Stem Cells, Tissue Engineering, Cell Culture, Cell-based Assays, machine learning, and computer vision

170 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Image Processing A.I. Synthetic Biology A.I. - Machine Learning

We design and supply artificial tissue environments for cell culture & bioprinting applications. Biogelx is helping people work in translational science, drug discovery and tissue engineering by 'making in vitro cell cultures more in vivo'​. We do this through manufacturing and supplying 3D cell cultures that can be tuned to specific tissues and synthetic bio-inks that are reproducible, scalable, easy to handle and suitable for clinical decision making. Our portfolio of biomaterials is comprised of synthetic peptide hydrogels that act as extracellular-matrix environments to support cell growth. In addition, the chemical and physical properties of our biomaterials can be precisely …

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your Partner in Cell Research / From Cell Research to Cell Analysis YOUR Partner in Cell Research - At OLS OMNI Life Science, we empower researchers and innovators in life sciences and biotechnology with smart, reliable, and user-friendly technologies that accelerate cell research and discovery. Driven by a commitment to people and partnership, we collaborate closely with scientists, organizations and our manufacturers to deliver solutions that make a real impact — from research to bioproduction. Our portfolio includes advanced tools and systems designed to enhance cell culture, flow cytometry, analysis, and imaging, enabling our partners to achieve meaningful results faster …

69 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology